Search clinical trials for: EOquin

Total 7 results

Spectrum Pharmaceuticals, Inc

Terminated

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Bladder Cancer

United States
Spectrum Pharmaceuticals, Inc

Completed

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

Bladder Cancer

United States
Spectrum Pharmaceuticals, Inc
Allergan

Terminated

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

United States, Poland, Czechia, Slovakia
Spectrum Pharmaceuticals, Inc

Completed

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Bladder Cancer

Canada, United States, Poland
Nippon Kayaku Co., Ltd.
Handok Inc.

Terminated

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Bladder Cancer

Japan, Korea, Republic of
Spectrum Pharmaceuticals, Inc
Allergan

Terminated

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Bladder Cancer

United States, Canada
Spectrum Pharmaceuticals, Inc

Completed

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Bladder Neoplasms

Netherlands

3

Subscribe